| Mahender Macha, MD | |
|
1100 E Michigan Ave, Suite 301, Jackson, MI 49201-1847 | |
| (517) 817-7605 | |
| (517) 817-7606 |
| Full Name | Mahender Macha |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 33 Years |
| Location | 1100 E Michigan Ave, Jackson, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558359596 | NPI | - | NPPES |
| 0015061690004 | Medicaid | PA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mclaren Greater Lansing | Lansing, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mclaren Greater Lansing | 7214833466 | 104 |
| Mclaren Flint | 8628975497 | 140 |
News Archive
Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.
Doctors routinely track their patients' hand-eye coordination to monitor any neuromuscular deficits, particularly as patients age or when they are injured - but the tests they have been using to track this kind of information may be subjective and qualitative.
Martek Biosciences Corporation (Nasdaq: MATK) announced that it intends to release the results of its third quarter of fiscal 2009 on September 2, 2009, at approximately 4:00 p.m. Eastern Time (ET). Following the release, at 4:45 p.m. ET Martek will conduct a conference call to discuss these results with investors. All interested parties may listen to the call live via webcast by visiting Martek's web site at http://investors.martek.com.
An important new study from the Laboratory for Developmental Genetics at USC has confirmed cytomegalovirus (CMV) as a cause of the most common salivary gland cancers. CMV joins a group of fewer than 10 identified oncoviruses - cancer-causing viruses - including HPV.
The federal government has allocated only about 2 percent of its transportation funds to encourage walking and cycling, not nearly enough to make a significant difference, according to Ralph Buehler, associate professor and chair of the urban affairs and planning program in the Virginia Tech School of Public and International Affairs.
› Verified 8 days ago
| Entity Name | W.a. Foote Memorial Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760437826 PECOS PAC ID: 0244136067 Enrollment ID: O20031212000691 |
News Archive
Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.
Doctors routinely track their patients' hand-eye coordination to monitor any neuromuscular deficits, particularly as patients age or when they are injured - but the tests they have been using to track this kind of information may be subjective and qualitative.
Martek Biosciences Corporation (Nasdaq: MATK) announced that it intends to release the results of its third quarter of fiscal 2009 on September 2, 2009, at approximately 4:00 p.m. Eastern Time (ET). Following the release, at 4:45 p.m. ET Martek will conduct a conference call to discuss these results with investors. All interested parties may listen to the call live via webcast by visiting Martek's web site at http://investors.martek.com.
An important new study from the Laboratory for Developmental Genetics at USC has confirmed cytomegalovirus (CMV) as a cause of the most common salivary gland cancers. CMV joins a group of fewer than 10 identified oncoviruses - cancer-causing viruses - including HPV.
The federal government has allocated only about 2 percent of its transportation funds to encourage walking and cycling, not nearly enough to make a significant difference, according to Ralph Buehler, associate professor and chair of the urban affairs and planning program in the Virginia Tech School of Public and International Affairs.
› Verified 8 days ago
| Entity Name | Mclaren Greater Lansing |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265600902 PECOS PAC ID: 7214833466 Enrollment ID: O20031217000526 |
News Archive
Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.
Doctors routinely track their patients' hand-eye coordination to monitor any neuromuscular deficits, particularly as patients age or when they are injured - but the tests they have been using to track this kind of information may be subjective and qualitative.
Martek Biosciences Corporation (Nasdaq: MATK) announced that it intends to release the results of its third quarter of fiscal 2009 on September 2, 2009, at approximately 4:00 p.m. Eastern Time (ET). Following the release, at 4:45 p.m. ET Martek will conduct a conference call to discuss these results with investors. All interested parties may listen to the call live via webcast by visiting Martek's web site at http://investors.martek.com.
An important new study from the Laboratory for Developmental Genetics at USC has confirmed cytomegalovirus (CMV) as a cause of the most common salivary gland cancers. CMV joins a group of fewer than 10 identified oncoviruses - cancer-causing viruses - including HPV.
The federal government has allocated only about 2 percent of its transportation funds to encourage walking and cycling, not nearly enough to make a significant difference, according to Ralph Buehler, associate professor and chair of the urban affairs and planning program in the Virginia Tech School of Public and International Affairs.
› Verified 8 days ago
| Entity Name | Mclaren Flint |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275807372 PECOS PAC ID: 8628975497 Enrollment ID: O20120620000454 |
News Archive
Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.
Doctors routinely track their patients' hand-eye coordination to monitor any neuromuscular deficits, particularly as patients age or when they are injured - but the tests they have been using to track this kind of information may be subjective and qualitative.
Martek Biosciences Corporation (Nasdaq: MATK) announced that it intends to release the results of its third quarter of fiscal 2009 on September 2, 2009, at approximately 4:00 p.m. Eastern Time (ET). Following the release, at 4:45 p.m. ET Martek will conduct a conference call to discuss these results with investors. All interested parties may listen to the call live via webcast by visiting Martek's web site at http://investors.martek.com.
An important new study from the Laboratory for Developmental Genetics at USC has confirmed cytomegalovirus (CMV) as a cause of the most common salivary gland cancers. CMV joins a group of fewer than 10 identified oncoviruses - cancer-causing viruses - including HPV.
The federal government has allocated only about 2 percent of its transportation funds to encourage walking and cycling, not nearly enough to make a significant difference, according to Ralph Buehler, associate professor and chair of the urban affairs and planning program in the Virginia Tech School of Public and International Affairs.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mahender Macha, MD Po Box 67000, Department 272801, Detroit, MI 48267-0002 Ph: (517) 817-7605 | Mahender Macha, MD 1100 E Michigan Ave, Suite 301, Jackson, MI 49201-1847 Ph: (517) 817-7605 |
News Archive
Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.
Doctors routinely track their patients' hand-eye coordination to monitor any neuromuscular deficits, particularly as patients age or when they are injured - but the tests they have been using to track this kind of information may be subjective and qualitative.
Martek Biosciences Corporation (Nasdaq: MATK) announced that it intends to release the results of its third quarter of fiscal 2009 on September 2, 2009, at approximately 4:00 p.m. Eastern Time (ET). Following the release, at 4:45 p.m. ET Martek will conduct a conference call to discuss these results with investors. All interested parties may listen to the call live via webcast by visiting Martek's web site at http://investors.martek.com.
An important new study from the Laboratory for Developmental Genetics at USC has confirmed cytomegalovirus (CMV) as a cause of the most common salivary gland cancers. CMV joins a group of fewer than 10 identified oncoviruses - cancer-causing viruses - including HPV.
The federal government has allocated only about 2 percent of its transportation funds to encourage walking and cycling, not nearly enough to make a significant difference, according to Ralph Buehler, associate professor and chair of the urban affairs and planning program in the Virginia Tech School of Public and International Affairs.
› Verified 8 days ago
Ashraf Shaaban Abdel Aziz Abou El Ela, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 205 N East Ave, Jackson, MI 49201 Phone: 517-205-4862 Fax: 517-205-1049 | |
Dr. Mohan Ganesh Kulkarni, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 900 E Michigan Ave, Suite 103, Jackson, MI 49201 Phone: 517-788-6007 Fax: 517-788-6438 | |
Vincent A Simonetti, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1100 E Michigan Ave, Suite 201, Jackson, MI 49201 Phone: 517-817-7605 Fax: 517-817-7606 |